Zacks Names CNC a Strong Buy Growth Stock, but DeepValue Report Maintains Caution

What happened

On May 28, 2026, Zacks Investment Research added Centene (CNC) to its Zacks Rank #1 (Strong Buy) growth stocks list, citing potential for growth. However, the latest DeepValue master report maintains a WAIT rating with a conviction of 3.5, reflecting deep-seated concerns about elevated health benefit ratios across ACA, Medicaid, and PDP lines, unresolved policy risks from the BBBA's proposed $1 trillion Medicaid cuts, and a $6.7 billion goodwill impairment that signals structurally lower earnings power. While the stock has rebounded from mid-2025 lows near $25 to ~$47, the report argues that the current price still prices in impaired returns and assumes HBR normalization that has not yet been proven. The DeepValue analysis highlights that despite aggressive 2026 ACA rate hikes (mid-30% increases), membership elasticity and adverse selection risks remain, and Medicaid HBR stayed at 93.4% in Q3 2025, far from the low-90s stabilization needed. Thus, the bullish Zacks call appears to reflect short-term sentiment and momentum rather than a fundamental turnaround, and the DeepValue thesis continues to favor waiting for either a cheaper entry near $38 or hard evidence of sustainable margin improvement by mid-2026.

Implication

The Zacks Strong Buy designation may attract momentum-driven buying and provide short-term support to CNC shares, but investors relying on the DeepValue framework should not interpret this as a change in the fundamental outlook. The DeepValue report outlines that the core issues—elevated HBR, policy risk from BBBA, and ACA morbidity—remain unresolved, and the current valuation near $47 leaves limited upside until Q4 2025 results and 2026 ACA enrollment data confirm margin improvement. For long-term holders, the recommendation is to maintain existing positions but not add, with an attractive entry zone near $38 and a re-assessment window in 6-12 months. The Zacks call may create a trading opportunity for nimble investors, but the underlying thesis suggests that the risk-reward is not compelling for new positions without proof of HBR trending toward 90%. In the near term, key catalysts to watch are Q4 2025 earnings (expected February 2026), S&P's CreditWatch resolution, and initial 2026 ACA enrollment figures, which will validate or invalidate the recovery narrative.

Thesis delta

No change to the DeepValue WAIT thesis. The Zacks upgrade is a positive sentiment signal but does not alter the fundamental assessment that Centene's margin recovery is unproven and policy risks are elevated. The thesis remains that the stock offers limited asymmetric upside until there is concrete evidence of ACA and Medicaid HBR stabilizing in the low-90s range.